Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth
Leili Ran(Memorial Sloan Kettering Cancer Center), Ping Chi(Memorial Sloan Kettering Cancer Center), Ingo K. Mellinghoff(Memorial Sloan Kettering Cancer Center), Inna Sirota(Memorial Sloan Kettering Cancer Center), William D. Tap(Memorial Sloan Kettering Cancer Center), Yuedan Chen(Memorial Sloan Kettering Cancer Center), Dong Gao(Chinese Academy of Sciences), Michael C. Kaufmann(Memorial Sloan Kettering Cancer Center), John Wongvipat(Memorial Sloan Kettering Cancer Center), Peter Besmer(Cornell University), Ferdinando Rossi(Neuroscience Institute), Takahiro Taguchi(Kochi Medical School Hospital), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Yu Chen(Memorial Sloan Kettering Cancer Center), Yuanyuan Xie(Beijing University of Chemical Technology), Devan Murphy(Memorial Sloan Kettering Cancer Center), Shipra Shukla(Memorial Sloan Kettering Cancer Center), Sinan Zhu(Wake Forest University), Zhen Cao(Memorial Sloan Kettering Cancer Center)
Cited by 119
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k